Characterisation of the Australian adult population living with asthma: Exacerbation frequency, long-term OCS use and adverse effects.

First published: 28/05/2021 Last updated: 21/02/2024



# Administrative details

#### **EU PAS number**

EUPAS41161

#### Study ID

44945

#### DARWIN EU® study

No

### **Study countries**

Australia

### **Study description**

The study employs a novel multi-modal approach to analyse, describe, and categorise the Australian adult asthmatic population based on factors such as their age, exacerbation frequency and OCS reliance. An audit of asthma classification and management in the primary care setting will also be conducted simultaneously. Understanding the demographics of Australian adults diagnosed with asthma and assessing existing management practices in primary care stands to offer insights into the burden of the disease in this country and how it could be reduced. The results of this study stand to be beneficial for both the patient's and the health care sector as identifying gaps in the management of asthma in the primary care setting can improve patient's asthma control thereby easing the burden on the Australian health care sector by limiting the number of avoidable asthma-related hospitalisations per year.

### Study status

Ongoing

# Research institutions and networks

## Institutions

# **Optimum Patient Care Australia**

Australia

First published: 01/02/2024

Last updated: 01/02/2024



# Networks

## **Optimum Patient Care (OPC) Network**

United Kingdom (Northern Ireland)

First published: 26/09/2015

Last updated: 16/06/2025

Network

(ENCePP partner)

Respiratory Effectiveness Group (REG)
Belgium
Denmark
France
Germany
Greece
Hungary
Italy
Netherlands
Spain
Sweden
United Kingdom
First published: 07/07/2021
Last updated: 04/06/2024
Network ENCePP partner

# Contact details

# Study institution contact

David Price dprice@opri.sg

Study contact

dprice@opri.sg

Primary lead investigator David Price

Primary lead investigator

# Study timelines

## Date when funding contract was signed

Actual: 01/05/2019

Study start date Actual: 01/05/2019

Date of final study report Planned: 31/12/2022

# Sources of funding

- Other
- Pharmaceutical company and other private sector

# More details on funding

AstraZeneca, Novartis, Optimum Patient Care Australia

# Regulatory

#### Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable

# Methodological aspects

Study type

# Study type list

Study type: Non-interventional study

## Scope of the study:

Disease epidemiology

### Main study objective:

The main objective of this study is the analysis and categorisation of the Australian adult population diagnosed with asthma.

# Study Design

#### Non-interventional study design

Cohort

# Study drug and medical condition

## Medical condition to be studied

Asthma

# Population studied

### Age groups

Adults (18 to < 46 years) Adults (46 to < 65 years) Adults (65 to < 75 years) Adults (75 to < 85 years) Adults (85 years and over)

## Estimated number of subjects

7868

# Study design details

## Outcomes

The primary outcome of this study is to define and describe the demographics of the Australian adult population diagnosed with asthma based various factors including their age, GINA step/category, exacerbation frequency and oral corticosteroid usage patterns across Australia. The secondary objective was to identify the extent of long-term OCS use in the Australian asthmatic population

#### Data analysis plan

Demographic features and management practices will be descriptively assessed. Statistical modelling will be conducted for OCS use and associated morbidities. The odds ratio computation will be made using logistic regression and a dependent variable of 1 when a specific comorbidity diagnostic detected in clinical notes, otherwise for each patient observation 0 was recorded. The independent variables will include the dummy variable 1 when the patient is considered as having severe asthma, 0 if the patient has mild or moderate asthma and other control variables such as age and gender. The unadjusted odds ratio will not include the control variable.

## Data management

## Data sources

#### Data source(s)

Optimum Patient Care Research Database Australia (OPCRDA)

#### Data sources (types)

Disease registry Electronic healthcare records (EHR) Other

#### Data sources (types), other

Prospective patient-based data collection

# Use of a Common Data Model (CDM)

### **CDM** mapping

No

# Data quality specifications

#### **Check conformance**

Unknown

#### **Check completeness**

Unknown

### **Check stability**

Unknown

## **Check logical consistency**

Unknown

# Data characterisation

## Data characterisation conducted

No